Treatment of type 2 diabetes

被引:5
|
作者
Meier, J. J. [1 ]
机构
[1] Klinikum Ruhr Univ Bochum, Univ Klinikum St Josef Hosp, Abt Diabetol, Gudrunstr 56, D-44791 Bochum, Germany
来源
INTERNIST | 2016年 / 57卷 / 02期
关键词
Metformin; Sulfonylurea compounds; Glucagon-like peptide 1 analogues; Dipeptidyl-peptidase; 4; inhibitors; Sodium-glucose transporter 2 inhibitors; JEJUNAL BYPASS LINER; CARDIOVASCULAR OUTCOMES; BARIATRIC SURGERY; GLYCEMIC CONTROL; METFORMIN; THERAPY; RISK; DAPAGLIFLOZIN; ASSOCIATION; MELLITUS;
D O I
10.1007/s00108-015-0002-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New glucose-lowering drugs have raised the complexity of diabetes treatment in recent years. While metformin is still the first choice in monotherapy for most cases, various options exist for dual combination therapy. In addition, combinations of three different oral glucose-lowering drugs are increasingly used. Insulin therapy is typically initiated using once daily administration of a long-acting insulin. If basal insulin alone is no longer sufficient, treatment can be intensified by adding short-acting insulin at mealtime or by combining basal insulin with oral glucose-lowering drugs or a glucagon-like peptide (GLP)-1 analogue. The choice of the most appropriate glucose-lowering drug should take into account not only the glucose-lowering efficacy, but also the side effect profile of the respective agents; economic factors must be considered as well. Modern treatment of type 2 diabetes should aim for near-normal glucose control.
引用
收藏
页码:153 / 165
页数:13
相关论文
共 50 条
  • [41] CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES
    Babu, A.
    DRUGS OF TODAY, 2013, 49 (06) : 363 - 376
  • [42] Sulfonylurea treatment in type 2 diabetes
    Bester, Kirstin
    Ton, Joey
    Korownyk, Christina
    CANADIAN FAMILY PHYSICIAN, 2018, 64 (04) : 295 - 295
  • [43] Empagliflozin for the treatment of Type 2 diabetes
    Komala, Muralikrishna Gangadharan
    Mather, Amanda
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (03) : 271 - 279
  • [44] Pioglitazone for the treatment of type 2 diabetes
    Nabrdalik, Katarzyna
    Cichocka, Edyta
    Zywiec, Joanna
    Chodkowski, Artur
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2014, 3 (04): : 176 - 180
  • [45] Alogliptin for the treatment of Type 2 diabetes
    Seino, Yutaka
    Yabe, Daisuke
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (06) : 547 - 559
  • [46] Treatment of type 2 diabetes mellitus
    Florence, JA
    Yeager, BF
    AMERICAN FAMILY PHYSICIAN, 1999, 59 (10) : 2835 - 2844
  • [47] Treatment of Diabetes mellitus Type 2
    Matthaei, S.
    Bierwirth, R.
    Fritsche, A.
    Gallwitz, B.
    Haering, H. -U.
    Joost, H. -G.
    Kellerer, M.
    Kloos, C.
    Kunt, T.
    Nauck, M.
    Schernthaner, G.
    Siegel, E.
    Thienel, F.
    DIABETOLOGIE UND STOFFWECHSEL, 2012, 7 : S124 - S129
  • [48] Dapagliflozin for the Treatment of Type 2 Diabetes
    Brooks, Arnie McCord
    Thacker, Stacey M.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (7-8) : 1286 - 1293
  • [49] Pharmacological treatment of type 2 diabetes
    Hermans, MP
    Buysschaert, M
    ACTA CLINICA BELGICA, 2004, 59 (02) : 59 - 66
  • [50] Inpatient Treatment of type 2 diabetes
    Meier, Juris J.
    DIABETOLOGIE UND STOFFWECHSEL, 2020, 15 (03) : 225 - 234